Revelation Biosciences (NASDAQ:REVB) Shares Up 4.8% – Should You Buy?

Revelation Biosciences, Inc. (NASDAQ:REVB) was up 4.8% during trading on Wednesday . The company traded as high as $1.11 and last traded at $1.09. 106,923 shares changed hands during mid-day trading, an increase of 155% from the average daily volume of 41,852 shares. The stock had previously closed at $1.04.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Revelation Biosciences Trading Up 3.5%

The company has a market capitalization of $4.57 million, a P/E ratio of -0.03 and a beta of -0.12. The company’s fifty day moving average is $1.03 and its 200 day moving average is $1.53.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.56). Equities research analysts predict that Revelation Biosciences, Inc. will post -4.99 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of REVB. Geode Capital Management LLC purchased a new position in Revelation Biosciences in the 4th quarter worth approximately $27,000. Armistice Capital LLC purchased a new position in shares of Revelation Biosciences in the third quarter worth $114,000. Finally, Sabby Management LLC raised its stake in shares of Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after acquiring an additional 398,651 shares during the last quarter. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.